Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...

Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft ...

The EFTISARC-NEO trial, with a data cut-off of 20 October 2024, also showed 71.4% of patients achieved a pathologic response ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...

This investigator-initiated, single-arm, open-label, phase 2 study evaluates the efficacy and safety of a triple combination regimen of pembrolizumab plus plinabulin/docetaxel. The study intends to ...

Pembrolizumab Maintenance Instead of Autologous Hematopoietic ... Trial Update from IMproveMF, an Ongoing, Open-Label, ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH ...

How have -- I know you just set up the payer team, but how have initial payer discussions been going for pembrolizumab and SMA ... Do not expect that we will have two doses in the label given the ...

TROPION-Lung01 is a global, randomised, multicentre, open-label Phase III trial evaluating the efficacy ... Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated ...